Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Is there a case for MDMA-assisted psychotherapy in the UK?

Journal of Psychopharmacology February 28, 2007 Ben Sessa 44 citations

Much has been written in scientific and popular literature in recent years about the dangers surrounding the recreational use of the drug MDMA/ecstasy. What is little known and understood however is the history of the apparently safe and effective use of MDMA as a therapeutic tool for psychotherapy. In this paper the author explores this history and describes the recent re-emergence of...

DOI: 10.1177/0269881107069029 (opens in new tab) MDMA Ecstasy Psychotherapist Recreational use +2

Electroconvulsive therapy in the treatment of depression in a former ecstasy user

Journal of Psychopharmacology November 1, 2006 Roland W. Freudenmann, Carlos Schönfeldt-lecuona, Manfred Spitzer et al. 4 citations

Depression in former ecstasy users may not respond to selective serotonin reuptake inhibitors (SSRIs) possibly due to damaged serotonergic synapses following long-term heavy ecstasy use. We report findings in a patient suffering from MDMA-induced depression which was refractory to several antidepressive medications including selective noradrenergic reuptake inhibitor (SNRI) and SSRI. An add-on...

The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.

Journal of Psychopharmacology September 1, 2006 Harry Sumnall, Jon C. Cole, Lisa Jerome 117 citations

Previous investigations of the subjective effects of MDMA (material sold as ecstasy) have conducted interviews and surveys of various groups of ecstasy users within particular sub-populations. This study examined subjective drug effects reported by different sub-populations of ecstasy users and explored whether the function or purpose served by using ecstasy influenced the nature of the drug...

Effects of psilocybin on time perception and temporal control of behaviour in humans

Journal of Psychopharmacology May 20, 2006 Marc Wittmann, Olivia Carter, Felix Hasler et al. 245 citations

Hallucinogenic psilocybin is known to alter the subjective experience of time. However, there is no study that systematically investigated objective measures of time perception under psilocybin. Therefore, we studied dose-dependent effects of the serotonin (5-HT) 2A/1A receptor agonist psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) on temporal processing, employing tasks of temporal...

DOI: 10.1177/0269881106065859 (opens in new tab) Psilocybin Time perception Cognition Hallucinogen +4

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA

Journal of Psychopharmacology May 20, 2006 Jiansong Yang, Masoud Jamei, Amir Heydari et al. 89 citations

The aim of this study was to model the in vivo kinetic consequences of mechanism-based inhibition (MBI) of CYP2D6 by 3,4 methylenedioxymethamphetamine (MDMA, ecstasy). A model with physiologically-based components of drug metabolism was developed, taking account of change in the hepatic content of active CYP2D6 due to MBI by MDMA. Based on the in vitro information, plasma concentration time...

Recreational ecstasy use and depression.

Journal of Psychopharmacology May 2006 Casey R. Guillot, David Greenway

Research in laboratory animals has shown that 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) destroys serotonergic axons in the brain at certain doses. Serotonin is known to take part in the regulation of mood in humans. Many researchers have hypothesized that if recreational ecstasy use destroys serotonergic axons, then a corresponding decline in the mood of ecstasy users should be seen....

Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study.

Journal of Psychopharmacology May 2006 Philip N. Murphy, Michelle Wareing, John E. Fisk

This self-report questionnaire study examined ecstasy users' perceptions of the risks associated with their use of ecstasy, their precautions against such risks, and its perceived effects on their lives. Gender differences in these areas were also explored. The sample comprised 328 ecstasy users (139 female, 187 male, one transsexual) with a mean age of 22.5 years (SD = 4.9 years)....

Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction

Journal of Psychopharmacology March 30, 2006 Boris B. Quednow, Frank Jessen, Kai‐uwe Kühn et al. 105 citations

Chronic administration of the common club drug 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is associated with long-term depletion of serotonin (5-HT) and loss of 5-HT axons in the brains of rodents and non-human primates, and evidence suggests that recreational MDMA consumption may also affect the human serotonergic system. Moreover, it was consistently shown that abstinent MDMA users...

Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994–2003)

Journal of Psychopharmacology March 30, 2006 Fabrizio Schifano, John Corkery, Paolo Deluca et al. 96 citations

In the last decade, a global trend of escalating ecstasy (MDMA, MDA, MDEA, MBDB) use was observed. Mentions on medical death certificates, last year's ecstasy use, number of drug offenders, seizures, prices and dosage levels figures were used for this descriptive and correlational study. Figures (1994ñ2003) were taken from the UK General Mortality Registers, from the Home Office Statistical...

MDMA polydrug users show processspecific central executive impairments coupled with impaired social and emotional judgement processes

Journal of Psychopharmacology March 30, 2006 Jonathon L. Reay, Colin Hamilton, David O. Kennedy et al. 91 citations

In recent years working memory de.cits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy). The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on ëprefrontalí mediated social and emotional judgement processes. Fifteen polydrug ecstasy users and 15 polydrug...

DOI: 10.1177/0269881106063269 (opens in new tab) MDMA Judgement Clinical psychology Social emotional learning +1

Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors

Journal of Psychopharmacology March 30, 2006 Kirstie Soar, John Turner, A. C. Parrott 65 citations

Recreational ecstasy (3,4-methylenedioxymethamphetamine; MDMA) use has been increasingly associated with a number of psychiatric symptoms and psychological problems. However, previous studies assessing possible psychopathological effects have not identified whether users consider their ecstasy use ‘problematic’ or not. In addition, research has generally failed to address the potential role of...

The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview

Journal of Psychopharmacology March 1, 2006 Euphrosyne Gouzoulis‐mayfrank, Jörg Daumann 179 citations

The popular dance drug ecstasy (3,4-methylenedioxymethamphetamine -- MDMA) is neurotoxic upon central serotonergic neurons in laboratory animals and possibly also in humans. In recent years, several studies reported alterations of serotonergic transmission and neuropsychiatric abnormalities in ecstasy users which might be related to MDMA-induced neurotoxic brain damage. To date, the most...

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective

Journal of Psychopharmacology March 1, 2006 Rainer Thomasius, P. Zapletalova, Kay Uwe Petersen et al. 158 citations

Although 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a known serotonergic neurotoxin in different animal species, there is to date no conclusive evidence of its neurotoxicity in humans. MDMA use was associated with impairments of psychological well-being, verbal memory and altered serotonergic functioning in a number of crosssectional studies. Due to inherent methodological...

A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers

Journal of Psychopharmacology March 1, 2006 G. J. H. Dumont, R. J. Verkes 148 citations

This review of the literature aims to identify the acute effects of MDMA (ecstasy) in healthy volunteers. The wide range of relevant but methodologically diverse tests was .rst grouped into clusters to allow an evaluation of tests that would otherwise have been excluded due to their low frequency of utilization. The following three types of tests were evaluated: (1) functional tests quantifying...

MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress

Journal of Psychopharmacology March 1, 2006 Andy C. Parrott 139 citations

Many recreational ecstasy/MDMA users display neuropsychobiological de.cits, whereas others remain problem free. This review will investigate some of the drug and non-drug factors which in.uence the occurrence of these de.cits. Acute and chronic MDMA usage are both important. Intensive use within a session is often associated with more problems. In term of lifetime usage, novice users generally...

Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls

Journal of Psychopharmacology March 1, 2006 C. T. J. Lamers, A. Bechara, M. Rizzo et al. 113 citations

Repeated ecstasy (MDMA) use is reported to impair cognition and cause increased feelings of depression and anxiety. Yet, many relevant studies have failed to control for use of drugs other than MDMA, especially marijuana (THC). To address these confounding effects we compared behavioural performance of 11 MDMA/THC users, 15 THC users and 15 non-drug users matched for age and intellect. We...

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects

Journal of Psychopharmacology March 1, 2006 Liesbeth Reneman, Maartje M. L. de Win, Wim van den Brink et al. 85 citations

Users of ecstasy (3,4-methylenedioxymethamphetamine; MDMA) may be at risk of developing MDMA-induced injury to the serotonin (5-HT) system. Previously, there were no methods available for directly evaluating the neurotoxic effects of MDMA in the living human brain. However, development of in vivoneuroimaging tools have begun to provide insights into the effects of ecstasy on the human brain....

DOI: 10.1177/0269881106061515 (opens in new tab) Ecstasy MDMA Serotonin transporter Neuroimaging +3

Pre-treatment with 3,4-methylenedioxymethamphetamine (MDMA) causes long-lasting changes in 5-HT2A receptor-mediated glucose utilization in the rat brain.

Journal of Psychopharmacology March 2006 Eleanor J Bull, Veronica Porkess, Michael Rigby et al.

The current study examined the long-term effect of brief exposure to 3,4-methylenedioxymethamphetamine (MDMA) on local cerebral glucose utilization (LCGU) in specific brain regions immediately following administration of the 5-HT2A/2C receptor agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Wistar rats (post-natal day (PND) 28, n = 24) were administered MDMA (5 mg/kg, i.p.) or...

Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro

Journal of Psychopharmacology March 1, 2006 Shaista Hayat, Robert J. Williams, Marcus Rattray

There is much evidence from animal studies that the recreational drug MDMA is a selective toxin which damages serotonin nerve terminals and axons. These in vivostudies show that an interaction between MDMA and the serotonin transporter protein (SERT) is the .rst step in toxicity. To further our understanding of the biochemical processes of MDMA toxicity we wished to use an in vitromodel for...

The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.

Journal of Psychopharmacology March 2006 Joanna K Huxster, Alessandro Pirona, Michael J Morgan

All previous studies of the sub-acute effects of ecstasy have failed to adequately control for group differences in psychopathology and past and concurrent substance use. The present study was designed to avoid these limitations. At an initial pre-drug baseline, a sample of 38 regular ecstasy users provided full substance histories and completed measures of personality and self-reported...

An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?

Journal of Psychopharmacology March 2006 Rosa Hoshi, Hannah Pratt, Sachin Mehta et al.

The lowering of serotonin for a period following MDMA use could account for the increases in both self-rated and objective measures of aggression previously found in ecstasy users several days after taking the drug. There is some evidence of gender differences in the acute, sub-acute and long-term effects of MDMA use, and given that gender differences have been found in aggression, it is...

Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.

Journal of Psychopharmacology March 2006 Jörg Daumann, Bianca Till, Thomas Fischermann et al.

Numerous animal studies have been able to demonstrate neurotoxic damage to central serotonergic systems after exposure to 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). It has been suggested that a high loudness dependence of auditory evoked potentials (LDAEP) and, particularly, of the tangential N1/P2 source activity is associated with a low functioning of serotonergic activity. Therefore,...

Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine

Journal of Psychopharmacology November 1, 2005 Kim P. C. Kuypers, Jan Ramaekers 88 citations

A range of studies has indicated that users of 3.4-Methylene-dioxymethamphetamine (MDMA, 'Ecstasy') display cognitive deficits, particularly memory impairment, as compared to non-drug using controls. Yet it is difficult to determine whether these deficits are caused by MDMA or some other confounding factor, such as polydrug use. The present study was designed to establish the direct relation...

New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ('Blue Mystic').

Journal of Psychopharmacology November 1, 2005 Fabrizio Schifano, Paolo Deluca, Lisa Agosti et al. 70 citations

2C-T-7 ('Blue Mystic'), an illicit compound which shows similarities with MDMA and other designer drugs, has been only occasionally identified in the EU, but discussion on the Internet between experimenters has recently grown significantly. We aimed at collecting together in a review the available information on 2C-T-7, both at the cyber and at the street market level. 2C-T-7 was first...

DOI: 10.1177/0269881105056660 (opens in new tab) Full text (opens in new tab) Online drug trends Digital drug trends Internet drug trends Cyber drug trends +16

The P3 in ‘ecstasy’ polydrug users during response inhibition and execution

Journal of Psychopharmacology September 1, 2005 Alex Gamma, Daniel Brandeis, Ruven Brandeis et al. 36 citations

Substance abuse and associated externalizing disorders are characterized by behavioural disinhibition and low impulse control, with reduced neural inhibition postulated to be the common underlying brain mechanism. The P3 component of event-related potentials (ERPs) is a widely used neurophysiological measure thought to reflect inhibitory brain processes, but as yet has not been assessed in...